At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,380 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Association Between Enhanced Sympathetic Activity and Cardiometabolic Complications: a Cross-sectional Study on Predictive Power of 24-hour Urinary Metanephrines (SYMPACT)
In Brief
An observational study for Catecholamine; Overproduction and 6 related conditions. Completed, enrolled 1,380 participants across 1 site.
Detailed Summary
Recent studies on catecholamine physiology have shown a direct correlation with arterial hypertension, overcoming the exclusive role in the diagnosis and follow-up of chromaffin tumors. Nevertheless, in literature, few studies explore and reveal the utility of testing metanephrines for the evaluation of sympathetic activity and its associated cardiometabolic complications in patients with essential hypertension.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCatecholamine; Overproduction, Catecholamine; Secretion, Metabolic Syndrome, Hypertensive Heart Disease, Hypertensive Kidney Disease, Diabetes Mellitus, Type 2, Hypertension,Essential
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
Primary CompletionJul 2015
Study CompletionJul 2020
First PostedJul 2020
TodayJul 2026
First PostedJul 31, 2020
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2015
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 5.9 years ago